One-year real-world outcomes after vericiguat initiation in heart failure: The ROVER-Japan cohort study
One-year real-world outcomes after vericiguat initiation in heart failure: The ROVER-Japan cohort study
M. Takeichi,Shun Kohsaka,7 Authors,Suguru Okami
TLDR
One-year follow-up of patients with HF after initiating vericiguat after initiating vericiguat found no change in the number of patients with HF or in the severity of their heart failure.
Abstract
Graphical abstract One-year follow-up of patients with HF after initiating vericiguat. *Defined as HFH in the previous six months or outpatient intravenous diuretics in the previous three months. **Parameters were assessed at pre- (day -90 to day -1) and post-vericiguat initiation periods (day 1 to day 90, day 91 to day 180). BNP, B-type natriuretic peptide; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HF, heart failure; HFH, heart failure hospitalization; MPR, medication possession ratio; WHF, worsening heart failure.